Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Sunday, November 15, 2020

Cancers, Vol. 12, Pages 3371: Promising Therapy in Lung Cancer: Spotlight on Aurora Kinases

Alexandros G.Sfakianakis shared this article with you from Inoreader
Μέσω Cancers

cancers-12-03371-ag-550.jpg

Cancers, Vol. 12, Pages 3371: Promising Therapy in Lung Cancer: Spotlight on Aurora Kinases

Cancers doi: 10.3390/cancers12113371

Authors: Domenico Galetta Lourdes Cortes-Dericks

Despite tremendous efforts to improve the treatment of lung cancer, prognosis still remains poor; hence, the search for efficacious therapeutic option remains a prime concern in lung cancer research. Cell cycle regulation including mitosis has emerged as an important target for cancer management. Novel pharmacological agents blocking the activities of regulatory molecules that control the functional aspects of mitosis such as Aurora kinases are now being investigated. The Aurora kinases, Aurora-A (AURKA), and Aurora B (AURKB) are overexpressed in many tumor entities such as lung cancer that correlate with poor survival, whereby their inhibition, in most cases, enhances the efficacy of chemo-and radiotherapies, indicating their implication in cancer therapy. The current knowledge on Aurora kinase inhibitors has increasingly shown high potential in ensuing targeted therapies in lung malignancies. In this review, we will briefly describe the biology of Aurora kinases, highlight thei r oncogenic roles in the pre-clinical and clinical studies in lung cancer and, finally, address the challenges and potentials of Aurora kinases to improve the therapy of this malignancy.

View on the web

No comments:

Post a Comment